TABLE 4.
Ongoing clinical trials for E‐selectin inhibitors (modified from clinicaltrials.gov)
| Ongoing: ClinicalTrials.Gov study numbers for GMI−1271 (Uproleselan) | |||
| AML (front line treatment) | NCT04964505 | Phase 1 | University of California, Davis |
| AML (relapsed/refractory) | NCT05054543 | Phase 3 | Apollomics, China |
| AML (treated secondary) | NCT04848974 | Phase 1b/2 | MD Anderson |
| AML (relapsed/refractory) | NCT03616470 | Phase 3 | Glycomimetics |
| AML (front line AML, >60 years) | NCT03701308 | Phase 2/3 | NCI/Alliance |
| AML, MDS, MPAL | NCT05146739 | Phase 1 | Children's Oncology Group |
| COVID−19 Pneumonia | NCT05057221 | Phase 1/2 | University of Michigan, Ann Arbor |
| Auto‐HCT for MM | NCT04682405 | Phase 2 | Washington University, St Louis |